2
|
Han Z, Chen W, Dong S, Yang C, Liu H, Pan Y, Yan L, Jiang Z. Highly Enantioselective Organocatalytic Sulfenylation of 3-Aryloxindoles. Org Lett 2012; 14:4670-3. [DOI: 10.1021/ol3021176] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Zhiqiang Han
- Institute of Chemical Biology and Key Laboratory of Natural Medicine and Immuno-Engineering of Henan Province, Henan University, Kaifeng, Henan, People’s Republic of China 475004, and Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543
| | - Wenchao Chen
- Institute of Chemical Biology and Key Laboratory of Natural Medicine and Immuno-Engineering of Henan Province, Henan University, Kaifeng, Henan, People’s Republic of China 475004, and Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543
| | - Sheng Dong
- Institute of Chemical Biology and Key Laboratory of Natural Medicine and Immuno-Engineering of Henan Province, Henan University, Kaifeng, Henan, People’s Republic of China 475004, and Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543
| | - Caiyun Yang
- Institute of Chemical Biology and Key Laboratory of Natural Medicine and Immuno-Engineering of Henan Province, Henan University, Kaifeng, Henan, People’s Republic of China 475004, and Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543
| | - Hongjun Liu
- Institute of Chemical Biology and Key Laboratory of Natural Medicine and Immuno-Engineering of Henan Province, Henan University, Kaifeng, Henan, People’s Republic of China 475004, and Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543
| | - Yuanhuang Pan
- Institute of Chemical Biology and Key Laboratory of Natural Medicine and Immuno-Engineering of Henan Province, Henan University, Kaifeng, Henan, People’s Republic of China 475004, and Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543
| | - Lin Yan
- Institute of Chemical Biology and Key Laboratory of Natural Medicine and Immuno-Engineering of Henan Province, Henan University, Kaifeng, Henan, People’s Republic of China 475004, and Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543
| | - Zhiyong Jiang
- Institute of Chemical Biology and Key Laboratory of Natural Medicine and Immuno-Engineering of Henan Province, Henan University, Kaifeng, Henan, People’s Republic of China 475004, and Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543
| |
Collapse
|
3
|
Modeling the molecular basis for α4β1 integrin antagonism. Bioorg Med Chem 2011; 19:5903-11. [PMID: 21889349 DOI: 10.1016/j.bmc.2011.08.011] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2011] [Revised: 07/29/2011] [Accepted: 08/05/2011] [Indexed: 11/23/2022]
Abstract
We report a 3D QSAR study of almost 300 structurally diverse small molecule antagonists of the integrin α4β1 whose biological activity spans six orders of magnitude. The alignment of the molecules was based on the conformation of a structurally related ligand bound to the αIIBβ3 and αvβ3 integrins in X-ray crystallographic studies. The molecular field method, CoMSIA, was used to generate the 3D QSAR models. The resulting models showed that the lipophilic properties were the most important, with hydrogen bond donor and steric properties less relevant. The models were highly significant (r(2)=0.89, q2(LOO)=0.67, r(2) (test set)=0.76), and could make robust predictions of the data (SEE=0.46, SEP=0.78, SEP (test set)=0.66). We predicted the antagonist activities of a further ten compounds with useful accuracy. The model appears capable of predicting α4β1 integrin antagonist activity to within a factor of five for compounds within its domain of applicability. The implications for design of improved integrin antagonists will be discussed.
Collapse
|
4
|
Gong Y, Kent Barbay J, Kimball ES, Santulli RJ, Carolyn Fisher M, Dyatkin AB, Miskowski TA, Hornby PJ, He W. Synthesis and SAR of pyridazinone-substituted phenylalanine amide α4 integrin antagonists. Bioorg Med Chem Lett 2008; 18:1331-5. [DOI: 10.1016/j.bmcl.2008.01.022] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2007] [Accepted: 01/07/2008] [Indexed: 10/22/2022]
|
5
|
Lassoie MA, Broeders F, Collart P, Defrère L, de Laveleye-Defais F, Demaude T, Gassama A, Guillaumet G, Hayez JC, Kiss L, Knerr L, Nicolas JM, Norsikian S, Quéré L, Routier S, Verbois V, Provins L. 2,6-Quinolinyl derivatives as potent VLA-4 antagonists. Bioorg Med Chem Lett 2007; 17:142-6. [PMID: 17035017 DOI: 10.1016/j.bmcl.2006.09.069] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2006] [Revised: 09/22/2006] [Accepted: 09/23/2006] [Indexed: 10/24/2022]
Abstract
A new series of 2,6-quinolinyl derivatives was prepared leading to potent low nanomolar VLA-4/VCAM-1 antagonists.
Collapse
|
6
|
Okigami H, Takeshita K, Tajimi M, Komura H, Albers M, Lehmann TE, Rölle T, Bacon KB. Inhibition of eosinophilia in vivo by a small molecule inhibitor of very late antigen (VLA)-4. Eur J Pharmacol 2006; 559:202-9. [PMID: 17234179 DOI: 10.1016/j.ejphar.2006.11.065] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2006] [Revised: 11/21/2006] [Accepted: 11/30/2006] [Indexed: 12/17/2022]
Abstract
The alpha4beta1 integrin (very late antigen-4, VLA-4) plays an important role in the migration of lymphocytes, monocytes, and eosinophils, but not neutrophils, to sites of inflammation. Pharmacological antagonism of VLA-4 is an attractive prospect for the treatment of predominantly eosinophil mediated diseases such as asthma and allergic rhinitis. We report here on a potent and selective, small molecule VLA-4 inhibitor, (2S)-3-(2', 5'-dichlorobiphenyl-4-yl)-2-({[1-(2-methoxybenzoyl)piperidin-3-yl]carbonyl}amino) propanoic acid, compound 1, and characterize the antagonist activities of this molecule in various cell-based assays and in an animal model of eosinophil migration. Compound 1 inhibited VLA-4/ vascular cell adhesion molecule-1(VCAM-1) interactions with in vitro potencies (IC50 value of 210 nM) in VLA-4-expressing Ramos cells, although the compound did not inhibit cell adhesion to fibronectin via alpha5beta1 integrin (very late antigen-5, VLA-5). Blockade of phorbol-12-myristate-13-acetate (PMA)- or Mn2+-stimulated VLA-4 interactions with compound 1 was observed in human T lymphocytes (IC50 value of 230 nM), human eosinophils (IC50 value of 4.0 microM) and mouse eosinophils (IC50 value of 1.6 microM). Furthermore, compound 1 administered by intraperitoneal injection inhibited eosinophil infiltration in a dose-dependent manner by up to 80% in an air pouch model. These data support the use of small molecule VLA-4 antagonists in the treatment of relevant diseases, such as asthma, atopic dermatitis, or allergic rhinitis.
Collapse
Affiliation(s)
- Hiromi Okigami
- Bayer Yakuhin, Ltd., Research Center Kyoto, Respiratory Disease Research, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Tong XS, Wang J, Zheng S, Pivnichny JV. High-throughput pharmacokinetics screen of VLA-4 antagonists by LC/MS/MS coupled with automated solid-phase extraction sample preparation. J Pharm Biomed Anal 2004; 35:867-77. [PMID: 15193731 DOI: 10.1016/j.jpba.2004.02.017] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2003] [Revised: 11/03/2003] [Accepted: 02/13/2004] [Indexed: 11/30/2022]
Abstract
Automation of plasma sample preparation for pharmacokinetic studies on VLA-4 antagonists has been achieved by using 96-well format solid-phase extraction operated by Beckman Coulter Biomek 2000 liquid handling system. A Biomek 2000 robot is used to perform fully automated plasma sample preparation tasks that include serial dilution of standard solutions, pipetting plasma samples, addition of standard and internal standard solutions, performing solid-phase extraction (SPE) on Waters OASIS 96-well plates. This automated sample preparation process takes less than 2 h for a typical pharmacokinetic study, including 51 samples, 24 standards, 9 quality controls, and 3-6 dose checks with minimal manual intervention. Extensive validation has been made to ensure the accuracy and reliability of this method. A two-stage vacuum pressure controller has been incorporated in the program to improve SPE efficiency. This automated SPE sample preparation approach combined with liquid chromatography coupled with the high sensitivity and selectivity of tandem mass spectrometry (LC/MS)/MS has been successfully applied on both individual and cassette dosing for pharmacokinetic screening of a large number of VLA-4 antagonists with a limit of quantitation in the range of 1-5 ng/ml. Consequently, a significant throughput increase has been achieved along with an elimination of tedious labor and its consequential tendency to produce errors.
Collapse
Affiliation(s)
- Xinchun S Tong
- Basic Chemistry, Merck Research Laboratory, Merck & Co. Inc., P.O. Box 2000, RY800-B205, Rahway, NJ 07065, USA.
| | | | | | | |
Collapse
|
9
|
Huryn DM, Ashwell S, Baudy R, Dressen DB, Gallaway W, Grant FS, Konradi A, Ley RW, Petusky S, Pleiss MA, Sarantakis D, Semko CM, Sherman MM, Tio C, Zhang L. Synthesis, characterization and evaluation of pro-drugs of VLA-4 antagonists. Bioorg Med Chem Lett 2004; 14:1651-4. [PMID: 15026043 DOI: 10.1016/j.bmcl.2004.01.062] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2003] [Accepted: 01/22/2004] [Indexed: 10/26/2022]
Abstract
A pro-drug strategy to identify orally efficacious VLA-4 antagonists is described. Potential pro-drugs were evaluated for their physical chemical characteristics and in vitro properties, including solubility, stability, permeability and plasma stability. Based on this characterization, promising compounds were identified for in vivo pharmacokinetic evaluation. These studies resulted in the identification of a pro-drug that exhibited desirable blood levels in PK studies in several different species.
Collapse
Affiliation(s)
- Donna M Huryn
- Chemical & Screening Sciences, Wyeth Research, CN 8000, Princeton, NJ 08543, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|